Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

Midatech Pharma announces confirmation of a €2.6 million EU Grant for further clinical development of MTX110 for the treatment of Diffuse Intrinsic Pontine Glioma, a rare and fatal form of childhood brain cancer
BiotechnologyRegulatory

Midatech Pharma announces confirmation of a €2.6 million EU Grant for further clinical development of MTX110 for the treatment of Diffuse Intrinsic Pontine Glioma, a rare and fatal form of childhood brain cancer

December 5, 2019 9:10 AM

LONDON, UK / ACCESSWIRE / December 5, 2019 / Midatech Pharma PLC ("Midatech" or the "Company") (AIM:MTPH.L; Nasdaq:MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that it has received confirmation of a €2.6 million EU grant to be used to conduct a ground-breaking clinical study, GlioKIDS, designed to demonstrate the efficacy of MTX110 as a treatment for...

Read more
American CryoStem Corporation Issues Shareholder Letter
BiotechnologyCompany UpdateShareholder Meeting

American CryoStem Corporation Issues Shareholder Letter

December 5, 2019 6:00 AM

EATONTOWN, NJ / ACCESSWIRE / December 5, 2019 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, issues the following letter on behalf of the CEO: Dear Fellow Shareholders: Business Partners and Friends: Nearing the end of 2019, I want to take this...

Read more
Updated Invitation & Agenda for Molecular Partners R&D Day 2019 - Dec. 12, 2019 - 7.30-10.00am - NYC
BiotechnologyInvestor Relations

Updated Invitation & Agenda for Molecular Partners R&D Day 2019 - Dec. 12, 2019 - 7.30-10.00am - NYC

December 3, 2019 11:30 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / December 3, 2019 / Molecular Partners AG (SIX:MOLN) Invitation We're looking forward to welcoming you at Molecular Partners' R&D Day on Thursday, December 12, 2019 from 7:30am to 10:00am. The event will take place at The Yale Club, 50 Vanderbilt Avenue, New York City. Click here for directions. Below is a detailed agenda of the event. If you have any questions about the event or in order...

Read more
Artelo Biosciences to Present at the 12th Annual LD Micro Main Event
BiotechnologyConferences

Artelo Biosciences to Present at the 12th Annual LD Micro Main Event

December 3, 2019 9:00 AM

LA JOLLA, CA / ACCESSWIRE / December 3, 2019 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the 12th Annual LD Micro Main Event being held on December 10-12, 2019 at the Luxe Sunset Bel Air Hotel in Bel Air, California. Gregory D. Gorgas, President and Chief Executive Officer of Artelo...

Read more
Edesa Biotech Reports Positive Healthy Volunteer Data  and Expands Phase 2b Dermatitis Study to Patients with Facial Lesions
BiotechnologyCompany Update

Edesa Biotech Reports Positive Healthy Volunteer Data and Expands Phase 2b Dermatitis Study to Patients with Facial Lesions

December 3, 2019 7:30 AM

TORONTO, ON / ACCESSWIRE / December 3, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported that the company's lead product candidate, EB01, has demonstrated positive safety data in healthy volunteers participating in its ongoing Phase 2b clinical study in chronic allergic contact dermatitis (ACD), a debilitating disease that is frequently caused by allergens present in the workplace. The...

Read more
SHAREHOLDER ALERT: COF MTCH PRU: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
BiotechnologyLawsuits

SHAREHOLDER ALERT: COF MTCH PRU: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

December 2, 2019 3:20 PM

NEW YORK, NY / ACCESSWIRE / December 2, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you. Capital One Financial Corporation (NYSE:COF) If you suffered a loss, contact us at:...

Read more
Molecular Partners to Participate in the Evercore ISI HealthCONx Conference
BiotechnologyConferences

Molecular Partners to Participate in the Evercore ISI HealthCONx Conference

December 2, 2019 11:30 AM

ZURICH-SCHLIEREN / ACCESSWIRE / December 2, 2019 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announced that Dr. Patrick Amstutz, CEO of Molecular Partners, will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019 at 12:50 - 1:20 PM Eastern Time (6:50 PM CET). The event will take...

Read more
Proteros, co-founder of Rodin Therapeutics, announces Rodin's acquisition by Alkermes
BiotechnologyCompany Update

Proteros, co-founder of Rodin Therapeutics, announces Rodin's acquisition by Alkermes

November 28, 2019 3:15 AM

MUNICH, GERMANY / ACCESSWIRE / November 28, 2019 / Proteros biostructures GmbH today announced that Rodin Therapeutics, Inc., a Boston, MA based biotech company developing novel, small molecule therapeutics for synaptopathies has been acquired by Alkermes plc, a global biopharmaceutical company headquartered in Dublin, Ireland. Rodin has been co-founded by Proteros in 2013. Rodin's security holders will receive an upfront payment of $100 million...

Read more
Dyadic Announces Achieving Human Like Glycan Structures From Its Engineered C1 Cell Line
BiotechnologyCompany Update

Dyadic Announces Achieving Human Like Glycan Structures From Its Engineered C1 Cell Line

November 25, 2019 8:00 AM

High G0 Glycosylation Level Driving Program Acceleration JUPITER, FL / ACCESSWIRE / November 25, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, announced...

Read more
Biotech Showcase Returns for Twelfth Year, Expecting Record Levels of Attendance and Capital
BiotechnologyConferences

Biotech Showcase Returns for Twelfth Year, Expecting Record Levels of Attendance and Capital

November 21, 2019 8:00 AM

NEW YORK, NY, SAN FRANCISCO, CA and CARLSBAD, CA / ACCESSWIRE / November 21, 2019 / Biotech Showcase™ is the investor conference that drives the future of therapeutic innovation, digital medicine, and international collaboration. Highlights from this year's programming include workshops and panels on emerging technologies, advances in therapeutic discovery and development, and predictions on the 2020 investment landscape. With more than $400...

Read more
Experion Holdings Ltd. Increases Distribution: Adds the Province of Manitoba, Alberta and Yukon to its Cannabis Supply Distribution Network
BiotechnologyCompany Update

Experion Holdings Ltd. Increases Distribution: Adds the Province of Manitoba, Alberta and Yukon to its Cannabis Supply Distribution Network

November 20, 2019 8:45 AM

VANCOUVER, BC / ACCESSWIRE / November 20, 2019 / Experion Holdings Ltd. (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31), is pleased to announce that its wholly-owned subsidiary Experion Biotechnologies Inc. ("Experion or "the Company''), a Health Canada licensed cultivator and processor of Cannabis, has been accepted by the Manitoba Liquor and Lotteries Corporation ("MBLL"), Alberta Gaming, Liquor & Cannabis and the Yukon Liquor Corporation as an...

Read more
Avalon GloboCare to Present at the 12th Annual LD Micro Main Event on December 10th
BiotechnologyConferences

Avalon GloboCare to Present at the 12th Annual LD Micro Main Event on December 10th

November 20, 2019 8:30 AM

FREEHOLD, NJ / ACCESSWIRE / November 20, 2019 / Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of cell-based technologies and therapeutics, today announced that management will present at the 12th Annual LD Micro Main Event institutional investor conference being held on December 10-12, 2019 at the Luxe Sunset Bel Air Hotel in Bel Air, California. David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon...

Read more
Hancock Jaffe Medical Team to Make Presentations at 46th Annual VEITH Vascular Symposium November 19 to November 23 in New York City
BiotechnologyConferences

Hancock Jaffe Medical Team to Make Presentations at 46th Annual VEITH Vascular Symposium November 19 to November 23 in New York City

November 19, 2019 8:31 AM

VenoValve and CoreoGraft to be Discussed at VEITH IRVINE, CA / ACCESSWIRE / November 19, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's VenoValve study in Colombia, and Dr. Marc H. Glickman, HJLI's Senior Vice President and Chief Medical Officer, will be making...

Read more
International Stem Cell Corporation Announces Financial Results for the Three and Nine-Months ended September 30, 2019
BiotechnologyEarnings

International Stem Cell Corporation Announces Financial Results for the Three and Nine-Months ended September 30, 2019

November 15, 2019 9:00 PM

CARLSBAD, CA / ACCESSWIRE / November 15, 2019 / International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today announced operating results for the three and nine months ended September 30, 2019. "As we mentioned before we completed the enrollment of the Phase I...

Read more
Hancock Jaffe Enrolls and Successfully Implants Tenth VenoValve Patient
BiotechnologyCompany Update

Hancock Jaffe Enrolls and Successfully Implants Tenth VenoValve Patient

November 15, 2019 1:00 PM

Initial Implantation Phase for First-in-Man Study Now Completed IRVINE, CA / ACCESSWIRE / November 15, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that it has enrolled and successfully implanted the 10th patient to complete the initial implantation phase of the first-in-man VenoValve study being conducted in Colombia. The surgery...

Read more
Taiwan Announced the Application of Cell Therapy, The Value of The Medical Industry was Improved
BiotechnologyCompany UpdateProduct Announcements

Taiwan Announced the Application of Cell Therapy, The Value of The Medical Industry was Improved

November 15, 2019 11:40 AM

Taiwan has top cell technology, and Guang-Li Biomedicine and Taipei Medical University Hospital have passed legal review in November, 2019. TAIPEI, TAIWAN / ACCESSWIRE / November 15, 2019 / In September last year, Taiwan announced the application method for cell therapy. Up to now, 27 medical institutions and 80 cell therapy applications are awaiting review, which is expected to increase medical output. Among them, Taipei Medical University...

Read more
Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update
BiotechnologyEarnings

Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update

November 15, 2019 8:30 AM

- Company ramps up activities to execute XCART's preclinical and regulatory strategy - - Cash runway expected to fund Company through preclinical advancements towards IND filing - FRAMINGHAM, MA / ACCESSWIRE / November 15, 2019 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized chimeric antigen receptor T cell ("CAR T") platform technology engineered...

Read more
Pieris Pharmaceuticals Announces Asthma-focused Translational Research Collaboration with the University of Pittsburgh
BiotechnologyCompany Update

Pieris Pharmaceuticals Announces Asthma-focused Translational Research Collaboration with the University of Pittsburgh

November 15, 2019 8:00 AM

BOSTON, MA / ACCESSWIRE / November 15, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced a research collaboration between the Company and the labs of University of Pittsburgh Professors Sally Wenzel, MD, and Anuradha Ray, PhD, focused on...

Read more
Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences
BiotechnologyCompany Update

Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

November 14, 2019 8:00 AM

BOSTON, MA / ACCESSWIRE / November 14, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor conferences: Jefferies 2019 London Healthcare...

Read more
avateramedical GmbH: CE Mark for avatera(R), the First German System for Robot-Assisted, Minimally Invasive Surgery, Setting the Foundation for Strategic Growth Plans
BiotechnologyManagement ChangesRegulatory

avateramedical GmbH: CE Mark for avatera(R), the First German System for Robot-Assisted, Minimally Invasive Surgery, Setting the Foundation for Strategic Growth Plans

November 14, 2019 5:00 AM

CE Mark for avatera(R), the First German System for Robot-Assisted, Minimally Invasive Surgery, Setting the Foundation for Strategic Growth Plans - Confirmation of safety and performance capability for all components of the avatera system enables European market entry - New, competitive player in the strongly growing robot-assisted surgery market - Introduction of the avatera system into everyday clinical practice in Europe and a...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?